规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mM * 1 mL in DMSO |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
1g |
|
||
Other Sizes |
|
体外研究 (In Vitro) |
体外:氯维地平和硝酸甘油均完全逆转U46619诱导的收缩(氯维地平(50%有效浓度[EC50] = 3.88 +/- 0.84 x 10(-6) mol/L,硝酸甘油EC50 = 4.84 +/- 2.76 x 10( -8) mol/L)。温度降低使氯维地平在血液中的半衰期增加,而血液稀释不影响氯维地平的体外半衰期。白蛋白浓度影响氯维地平在红细胞中的水解率用生理盐水悬浮
|
||
---|---|---|---|
体内研究 (In Vivo) |
氯维地平是一种高清除率药物,分布体积相对较小,导致所有研究物种的半衰期极短。兔子、大鼠和狗的个体值初始半衰期中位数(贝叶斯估计)分别为 12、20 和 22 秒。极高的清除率和较小的分布体积导致氯维地平的半衰期较短,分别为 2.2 分钟和 16.8 分钟。产生一半最大效应(即EC50和ED50)的血液浓度和剂量率分别约为25nM和1.5μg/kg/min。
|
||
动物实验 |
|
||
药代性质 (ADME/PK) |
Absorption, Distribution and Excretion
urine 63-74%, feces 7-22% Metabolism / Metabolites Clevidipine is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood. Biological Half-Life 1 minute |
||
毒性/毒理 (Toxicokinetics/TK) |
Protein Binding
>99.5% |
||
参考文献 |
J Pediatr Pharmacol Ther.2015Jan-Feb;20(1):54-60.
|
||
其他信息 |
Clevidipine is a dihydropyridine.
Clevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option. Clevidipine is a Dihydropyridine Calcium Channel Blocker. The mechanism of action of clevidipine is as a Calcium Channel Antagonist. Drug Indication For the reduction of blood pressure when when oral antihypertensive therapy is not feasible or not desirable. FDA Label Treatment of hypertensive disease Mechanism of Action Possibly by deforming the channel, inhibiting ion-control gating mechanisms, and/or interfering with the release of calcium from the sarcoplasmic reticulum, clevidipine inhibits the influx of extracellular calcium across both the myocardial and vascular smooth muscle cell membranes. The resultant inhibition of the contractile processes of the myocardial smooth muscle cells leads to dilation of the coronary and systemic arteries and improved oxygen delivery to the myocardial tissue. Pharmacodynamics Clevidipine belongs to a well-known class of drugs called dihydropyridine calcium channel antagonists. Clevidpine is the first third generation intravenous dihydropyridine calcium channel blocker. In vitro studies demonstrated that clevidipine acts by selectively relaxing the smooth muscle cells that line small arteries, resulting in arterial dilation, widening of the artery opening, and without reducing central venous pressure or reducing cardiac output. |
分子式 |
C21H23CL2NO6
|
|
---|---|---|
分子量 |
456.32
|
|
精确质量 |
455.09
|
|
CAS号 |
167221-71-8
|
|
相关CAS号 |
Clevidipine-d7;(R)-Clevidipine-13C,d3
|
|
PubChem CID |
153994
|
|
外观&性状 |
White to off-white solid powder
|
|
密度 |
1.3±0.1 g/cm3
|
|
沸点 |
539.7±50.0 °C at 760 mmHg
|
|
熔点 |
128-130°C
|
|
闪点 |
280.2±30.1 °C
|
|
蒸汽压 |
0.0±1.4 mmHg at 25°C
|
|
折射率 |
1.543
|
|
LogP |
5.46
|
|
tPSA |
90.93
|
|
氢键供体(HBD)数目 |
1
|
|
氢键受体(HBA)数目 |
7
|
|
可旋转键数目(RBC) |
10
|
|
重原子数目 |
30
|
|
分子复杂度/Complexity |
748
|
|
定义原子立体中心数目 |
0
|
|
InChi Key |
KPBZROQVTHLCDU-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C21H23Cl2NO6/c1-5-7-15(25)29-10-30-21(27)17-12(3)24-11(2)16(20(26)28-4)18(17)13-8-6-9-14(22)19(13)23/h6,8-9,18,24H,5,7,10H2,1-4H3
|
|
化学名 |
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
|
|
别名 |
|
|
HS Tariff Code |
2934.99.9001
|
|
存储方式 |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month 注意: 本产品在运输和储存过程中需避光。 |
|
运输条件 |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
溶解度 (体外实验) |
|
|||
---|---|---|---|---|
溶解度 (体内实验) |
配方 1 中的溶解度: ≥ 2.5 mg/mL (5.48 mM) (饱和度未知) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。
例如,若需制备1 mL的工作液,可将100 μL 25.0 mg/mL澄清DMSO储备液加入到400 μL PEG300中,混匀;然后向上述溶液中加入50 μL Tween-80,混匀;加入450 μL生理盐水定容至1 mL。 *生理盐水的制备:将 0.9 g 氯化钠溶解在 100 mL ddH₂O中,得到澄清溶液。 配方 2 中的溶解度: ≥ 2.5 mg/mL (5.48 mM) (饱和度未知) in 10% DMSO + 90% Corn Oil (这些助溶剂从左到右依次添加,逐一添加), 澄清溶液。 例如,若需制备1 mL的工作液,可将 100 μL 25.0 mg/mL 澄清 DMSO 储备液加入到 900 μL 玉米油中并混合均匀。 请根据您的实验动物和给药方式选择适当的溶解配方/方案: 1、请先配制澄清的储备液(如:用DMSO配置50 或 100 mg/mL母液(储备液)); 2、取适量母液,按从左到右的顺序依次添加助溶剂,澄清后再加入下一助溶剂。以 下列配方为例说明 (注意此配方只用于说明,并不一定代表此产品 的实际溶解配方): 10% DMSO → 40% PEG300 → 5% Tween-80 → 45% ddH2O (或 saline); 假设最终工作液的体积为 1 mL, 浓度为5 mg/mL: 取 100 μL 50 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀/澄清;向上述体系中加入50 μL Tween-80,混合均匀/澄清;然后继续加入450 μL ddH2O (或 saline)定容至 1 mL; 3、溶剂前显示的百分比是指该溶剂在最终溶液/工作液中的体积所占比例; 4、 如产品在配制过程中出现沉淀/析出,可通过加热(≤50℃)或超声的方式助溶; 5、为保证最佳实验结果,工作液请现配现用! 6、如不确定怎么将母液配置成体内动物实验的工作液,请查看说明书或联系我们; 7、 以上所有助溶剂都可在 Invivochem.cn网站购买。 |
制备储备液 | 1 mg | 5 mg | 10 mg | |
1 mM | 2.1914 mL | 10.9572 mL | 21.9144 mL | |
5 mM | 0.4383 mL | 2.1914 mL | 4.3829 mL | |
10 mM | 0.2191 mL | 1.0957 mL | 2.1914 mL |
1、根据实验需要选择合适的溶剂配制储备液 (母液):对于大多数产品,InvivoChem推荐用DMSO配置母液 (比如:5、10、20mM或者10、20、50 mg/mL浓度),个别水溶性高的产品可直接溶于水。产品在DMSO 、水或其他溶剂中的具体溶解度详见上”溶解度 (体外)”部分;
2、如果您找不到您想要的溶解度信息,或者很难将产品溶解在溶液中,请联系我们;
3、建议使用下列计算器进行相关计算(摩尔浓度计算器、稀释计算器、分子量计算器、重组计算器等);
4、母液配好之后,将其分装到常规用量,并储存在-20°C或-80°C,尽量减少反复冻融循环。
计算结果:
工作液浓度: mg/mL;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL)。如该浓度超过该批次药物DMSO溶解度,请首先与我们联系。
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
(1) 请确保溶液澄清之后,再加入下一种溶剂 (助溶剂) 。可利用涡旋、超声或水浴加热等方法助溶;
(2) 一定要按顺序加入溶剂 (助溶剂) 。
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT05783557 | Not yet recruiting | Drug: Clevidipine Butyrate Injectable Emulsion Drug: Cleviprex® |
Hypertensive Emergency | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. |
May 1, 2023 | Phase 3 |
NCT00978822 | Terminated | Drug: Clevidipine butyrate injectable emulsion |
Subarachnoid Hemorrhage Hypertension |
Henry Ford Health System | June 2009 | Phase 2 |
NCT05922436 | Not yet recruiting | Drug: QLG2071 Drug: Cleviprex® |
Hypertensive Emergency | Qilu Pharmaceutical (Hainan) Co., Ltd. |
July 15, 2023 | Phase 3 |
NCT04670809 | Unknown | Drug: Clevidipine Butyrate Injection Drug: Ncardipine Hydrochloride Injection |
Hypertensive Emergency | Nanjing Yoko Biomedical Co., Ltd. |
July 27, 2020 | Phase 3 |
NCT01526876 | Withdrawn | Drug: clevidipine butyrate | Hypertension | Columbia University | November 2011 | Phase 4 |